Details of the Drug

General Information of Drug (ID: DMD1QXW)

Drug Name
Ambrisentan
Synonyms
Letairis; Ambrisentan [INN]; Gilead brand of ambrisentan; BSF 208075; BSF208075; LU 208075; LU208075; BSF-208075; LU-208075; Benzenepropanoic acid, .alpha.-[(4,6-dimethyl-2-pyrimidinyl)oxy]-.beta.-methoxy-.beta.-phe; (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-methoxy-3,3-diphenylpropanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenyl-propanoic acid; 2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid; 2-[(4,6-dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid
Indication
Disease Entry ICD 11 Status REF
Pulmonary arterial hypertension BB01.0 Approved [1], [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 378.4
Topological Polar Surface Area (xlogp) 3.8
Rotatable Bond Count (rotbonds) 7
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 2 h [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [4]
Clearance
The apparent oral clearance of drug is 38 mL/min [5]
Elimination
5% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 15 hours [6]
Metabolism
The drug is metabolized via uridine 5-diphosphate glucuronosyltransferases (UGTs) 1A9S, 2B7S,1A3S to form ambrisentan glucuronide [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.3795 micromolar/kg/day [7]
Water Solubility
The ability of drug to dissolve in water is measured as 0.06 mg/mL [4]
Chemical Identifiers
Formula
C22H22N2O4
IUPAC Name
(2S)-2-(4,6-dimethylpyrimidin-2-yl)oxy-3-methoxy-3,3-diphenylpropanoic acid
Canonical SMILES
CC1=CC(=NC(=N1)O[C@H](C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C
InChI
InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1
InChIKey
OUJTZYPIHDYQMC-LJQANCHMSA-N
Cross-matching ID
PubChem CID
6918493
ChEBI ID
CHEBI:135949
CAS Number
177036-94-1
DrugBank ID
DB06403
TTD ID
D0X5ZI
VARIDT ID
DR00311
INTEDE ID
DR0080
ACDINA ID
D00028

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Endothelin A receptor (EDNRA) TTKRD0G EDNRA_HUMAN Antagonist [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [9]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [10]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [10]
UDP-glucuronosyltransferase 2B7 (UGT2B7)
Main DME 		DEB3CV1 UD2B7_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A9 (UGT1A9)
Main DME 		DE85D2P UD19_HUMAN Substrate [10]
UDP-glucuronosyltransferase 1A3 (UGT1A3)
Main DME 		DEF2WXN UD13_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Pulmonary arterial hypertension
ICD Disease Classification BB01.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Endothelin A receptor (EDNRA) DTT EDNRA 3.19E-05 -2.69 -1.71
P-glycoprotein 1 (ABCB1) DTP P-GP 2.55E-01 4.83E-01 5.66E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 1.39E-02 -2.78E-01 -5.67E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.10E-01 -1.23E-01 -2.88E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Ambrisentan (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Midostaurin DMI6E0R Moderate Decreased clearance of Ambrisentan due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [64]
Arn-509 DMT81LZ Moderate Increased metabolism of Ambrisentan caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [65]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Ambrisentan and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [66]
Ag-221 DMS0ZBI Moderate Decreased clearance of Ambrisentan due to the transporter inhibition by Ag-221. BCR-ABL1-negative chronic myeloid leukaemia [2A41] [67]
Erdafitinib DMI782S Moderate Decreased clearance of Ambrisentan due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [68]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Ambrisentan and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [69]
Tucatinib DMBESUA Minor Decreased metabolism of Ambrisentan caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [64]
PF-04449913 DMSB068 Moderate Decreased clearance of Ambrisentan due to the transporter inhibition by PF-04449913. Chronic myelomonocytic leukaemia [2A40] [65]
Ivacaftor DMZC1HS Moderate Decreased clearance of Ambrisentan due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [70]
MK-8228 DMOB58Q Moderate Decreased clearance of Ambrisentan due to the transporter inhibition by MK-8228. Cytomegaloviral disease [1D82] [71]
Boceprevir DMBSHMF Minor Decreased metabolism of Ambrisentan caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [64]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Ambrisentan and Brentuximab vedotin. Hodgkin lymphoma [2B30] [72]
Fostemsavir DM50ILT Moderate Decreased clearance of Ambrisentan due to the transporter inhibition by Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [73]
Cobicistat DM6L4H2 Minor Decreased metabolism of Ambrisentan caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [64]
Etravirine DMGV8QU Moderate Increased metabolism of Ambrisentan caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [74]
Bempedoic acid DM1CI9R Moderate Decreased clearance of Ambrisentan due to the transporter inhibition by Bempedoic acid. Hyper-lipoproteinaemia [5C80] [75]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Ambrisentan and Teriflunomide. Hyper-lipoproteinaemia [5C80] [76]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Ambrisentan and BMS-201038. Hyper-lipoproteinaemia [5C80] [77]
Ceritinib DMB920Z Minor Decreased metabolism of Ambrisentan caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [64]
PF-06463922 DMKM7EW Moderate Increased metabolism of Ambrisentan caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [78]
Capmatinib DMYCXKL Moderate Decreased clearance of Ambrisentan due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [79]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Ambrisentan and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [80]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Ambrisentan and Idelalisib. Mature B-cell leukaemia [2A82] [81]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Ambrisentan caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [65]
Lasmiditan DMXLVDT Moderate Decreased clearance of Ambrisentan due to the transporter inhibition by Lasmiditan. Migraine [8A80] [82]
Lefamulin DME6G97 Moderate Decreased metabolism of Ambrisentan caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [83]
Lonafarnib DMGM2Z6 Minor Decreased metabolism of Ambrisentan caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [64]
Enzalutamide DMGL19D Moderate Increased metabolism of Ambrisentan caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [84]
Darolutamide DMV7YFT Moderate Decreased clearance of Ambrisentan due to the transporter inhibition by Darolutamide. Prostate cancer [2C82] [65]
Armodafinil DMGB035 Minor Increased metabolism of Ambrisentan caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [85]
Fostamatinib DM6AUHV Moderate Decreased clearance of Ambrisentan due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [86]
⏷ Show the Full List of 31 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Carmellose sodium E00625 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 3350 E00652 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Soybean lecithin E00637 Not Available Other agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ambrisentan 10 mg tablet 10 mg Oral Tablet Oral
Ambrisentan 5 mg tablet 5 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3951).
2 Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
9 Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin Pharmacol Ther. 2010 Oct;88(4):513-20.
10 Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
21 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
22 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
23 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
24 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
25 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
26 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
27 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
28 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
29 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
30 Metabolism and transport of tamoxifen in relation to its effectiveness: new perspectives on an ongoing controversy. Future Oncol. 2014 Jan;10(1):107-22.
31 Determination of UDP-glucuronosyltransferase UGT2B7 activity in human liver microsomes by ultra-performance liquid chromatography with MS detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Jul 1;870(1):84-90.
32 Pharmacokinetic and pharmacodynamic interaction of lorazepam and valproic acid in relation to UGT2B7 genetic polymorphism in healthy subjects. Clin Pharmacol Ther. 2008 Apr;83(4):595-600.
33 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
34 Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
35 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
36 Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet. 2005;44(5):467-94.
37 Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
38 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
39 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
40 UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
41 Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
42 Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
43 Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
44 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
45 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
46 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
47 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
48 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
49 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
50 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
51 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
52 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
53 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
54 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
55 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
56 Influence of endothelin receptor antagonists on myocardial protein kinase C isoforms in uraemic cardiomyopathy. Clin Sci (Lond). 2002 Aug;103 Suppl 48:276S-279S.
57 Effects of a selective ET(A)-receptor antagonist, atrasentan (ABT-627), in murine models of allergic asthma: demonstration of mouse strain specificity. Clin Sci (Lond). 2002 Aug;103 Suppl 48:367S-370S.
58 Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subar... Acta Neurochir (Wien). 2007;149(9):911-8; discussion 918.
59 Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem. 2005 Oct 20;48(21):6523-43.
60 Pfizer. Product Development Pipeline. March 31 2009.
61 Endothelin ETA receptor blockade with darusentan increases sodium and potassium excretion in aging rats. J Cardiovasc Pharmacol. 2006 Mar;47(3):456-62.
62 Endothelin in heart failure: a promising therapeutic target Heart. 1997 Feb;77(2):93-4.
63 Reduction of bFGF-induced smooth muscle cell proliferation and endothelin receptor mRNA expression by mevastatin and atorvastatin. Biochem Pharmacol. 2002 Aug 1;64(3):497-505.
64 Product Information. Letairis (ambrisentan). Gilead Sciences, Foster City, CA.
65 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
66 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
67 Cerner Multum, Inc. "Australian Product Information.".
68 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
69 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
70 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
71 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
72 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
73 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
74 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
75 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
76 Canadian Pharmacists Association.
77 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
78 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
79 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
80 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
81 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
82 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
83 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
84 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
85 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
86 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.